Amryt Pharma advancing on multiple fronts

  • Amryt Pharma new drug application won’t go through advisory committee
  • Amryt Pharma boss ‘really pleased’ with FY results, on 18.5% increase in revenue year-over-year
Amryt Pharma PLC -

Quick facts: Amryt Pharma PLC


View company profile

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.

The company has a strong and growing portfolio of commercial and development assets.

07 Jun 2021

( ) said the US Food and Drug Administration had confirmed its New Drug Application (NDA) for Oleogel-S10 does not require an Advisory Committee meeting.

Oleogel-S10 was developed to treat junctional and dystrophic epidermolysis bullosa (EB), where the skin is fragile to even the lightest touch.

It is a rare condition that affects young children and adults and there is currently no approved treatment.

An FDA advisory committee is an independent body that gives direction to the agency over a product applying for approval.

Read more

03 Jun 2021

(NASDAQ:AMYT; ) was granted a priority review of its new drug application for Oleogel-S10 by the US Food & Drug Administration with a decision expected on or before November 30.

The watchdog’s fast-track has shortened the regulatory timeline from 10 months to six.

Read more

02 Jun 2021

‘s (NASDAQ:AMYT, ) new drug application for its potential treatment for epidermolysis bullosa (EB) has been approved by the US regulator.

The Food and Drug Administration (FDA) accepted Amrty’s application for Oleogel-S10 to be approved as a treatment for cutaneous manifestations of junctional and dystrophic EB, which affects adults and young children and for which there is no currently approved treatment.

Read more

04 Mar 2021

() () CEO Joey Wiley tells Proactive it expects to continue strong sales growth for 2021 after reporting a first underlying profit and strong cash flow for the past year.

Wiley says the biopharma company, which acquires, develops and commercializes novel treatments for rare diseases, generated revenue growth of 18.5% to US$182.6M for 2020 from its two products on the market, metreleptin as a supplement for people with leptin deficiency and lomitapide, for adults with a rare cholesterol disorder.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…


Market Report: FTSE falls as Deliveroo fails to deliver on listing debut

FTSE 100 slipped back after US stocks were pressured by rising treasury yields and inflation concerns. London’s leading index shed 16 points to 6,744 in early dealings with a dismal start to trading by Deliveroo also dampening the mood.

Having been priced at 390p, the bottom of its…

on 31/3/21

3 min read


Please enter your comment!
Please enter your name here